Tanase Daniela Maria, Gosav Evelina Maria, Ouatu Anca, Badescu Minerva Codruta, Dima Nicoleta, Ganceanu-Rusu Ana Roxana, Popescu Diana, Floria Mariana, Rezus Elena, Rezus Ciprian
Department of Internal Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.
Internal Medicine Clinic, "Sf. Spiridon" County Clinical Emergency Hospital Iasi, 700111 Iasi, Romania.
Life (Basel). 2021 Oct 8;11(10):1057. doi: 10.3390/life11101057.
Regardless of the newly diagnostic and therapeutic advances, coronary artery disease (CAD) and more explicitly, ST-elevation myocardial infarction (STEMI), remains one of the leading causes of morbidity and mortality worldwide. Thus, early and prompt diagnosis of cardiac dysfunction is pivotal in STEMI patients for a better prognosis and outcome. In recent years, microRNAs (miRNAs) gained attention as potential biomarkers in myocardial infarction (MI) and acute coronary syndromes (ACS), as they have key roles in heart development, various cardiac processes, and act as indicators of cardiac damage. In this review, we describe the current available knowledge about cardiac miRNAs and their functions, and focus mainly on their potential use as novel circulating diagnostic and prognostic biomarkers in STEMI.
尽管有新的诊断和治疗进展，但冠状动脉疾病（CAD），更确切地说是ST段抬高型心肌梗死（STEMI），仍然是全球发病和死亡的主要原因之一。因此，早期和及时诊断心脏功能障碍对于STEMI患者获得更好的预后和结局至关重要。近年来，微小RNA（miRNA）作为心肌梗死（MI）和急性冠状动脉综合征（ACS）的潜在生物标志物受到关注，因为它们在心脏发育、各种心脏过程中起关键作用，并作为心脏损伤的指标。在本综述中，我们描述了关于心脏miRNA及其功能的现有知识，并主要关注它们作为STEMI新型循环诊断和预后生物标志物的潜在用途。
Zotero 插件